AI-built company narrative
A profile claims a company valued at about $1.8 billion operates with just two employees, arguing AI enables extreme scale with tiny teams. The story presents the model as a market narrative about capital-efficient operations enabled by AI, rather than broad proof of repeatability. (indianexpress.com)
A Los Angeles telehealth startup called Medvi says it is on pace for $1.8 billion in 2026 sales with just two employees: founder Matthew Gallagher and his brother Elliot. (nytimes.com) Gallagher told The New York Times he built Medvi in about two months from his house with $20,000 and more than a dozen artificial intelligence tools. The company sells online access to weight-loss care built around glucagon-like peptide-1, or GLP-1, drugs. (nytimes.com) In 2025, Medvi generated $401 million in sales, reached 250,000 customers and posted a 16.2 percent net margin, according to financials reviewed by the Times. Gallagher hired Elliot after that first full year, leaving the company with two employees. (forbes.com) The basic pitch is simple: use software to do work that once required departments. Gallagher used artificial intelligence to write code, generate ad copy and images, handle customer service and monitor performance, while doctors, pharmacies and other outside partners handled the regulated medical work. (nytimes.com) That model fits a line Sam Altman pushed in 2024, when he said artificial intelligence could make a one-person billion-dollar company possible. Medvi became the example people started pointing to after the Times profile ran on April 2. (indianexpress.com) The story is also about the market Medvi chose. GLP-1 weight-loss drugs created a rush of telehealth middlemen, and Medvi entered in September 2024 against established companies including Hims & Hers and Ro. (forbes.com) The tiny headcount does not mean two people treat hundreds of thousands of patients by themselves. Medvi’s site says care is delivered by licensed providers and supported by medical assistants and dietitians, showing that the two-employee claim refers to direct company payroll, not the full network behind the service. (medvi.org) The narrative ran into a harder fact on February 20, 2026, when the Food and Drug Administration sent Medvi a warning letter over marketing for compounded semaglutide and tirzepatide. The agency said the website made false or misleading claims and suggested Medvi was the compounder when it was not. (fda.gov) Medvi said in an April 8 statement that the Food and Drug Administration letter named the address medvi.io, not its current medvi.org site, and said the agency had sent similar letters to dozens of telehealth companies. The company said outside speculation had mixed together separate issues. (medvi.org) So the Medvi story is two things at once: a real example of artificial intelligence shrinking the staff needed to build and market a fast-growing company, and a reminder that health care still runs into regulators, partners and compliance rules that software alone does not erase. (nytimes.com)
